Related references
Note: Only part of the references are listed.hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
Sheron Perera et al.
CLINICAL CANCER RESEARCH (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
Jerome Raffenne et al.
CANCERS (2019)
The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival
Xin-Zhe Yu et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2017)
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer
Yasuhiro Yabushita et al.
ANTICANCER RESEARCH (2017)
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
N. T. E. Bird et al.
BRITISH JOURNAL OF SURGERY (2017)
Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Xiaoyu Liu et al.
MEDICINE (2016)
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody
Steffen Ormanns et al.
EUROPEAN JOURNAL OF CANCER (2014)
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
William Greenhalf et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
Zhu-Qing Liu et al.
PLOS ONE (2014)
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
Stina Nordh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy
Soichiro Morinaga et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphael Marechal et al.
GASTROENTEROLOGY (2012)
Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy
Yasuhiro Murata et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine
Natsuko Kawada et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer
D. Ansari et al.
BRITISH JOURNAL OF SURGERY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
C. W. Michalski et al.
BRITISH JOURNAL OF CANCER (2008)
Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3
Hai-Biao Jiang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
Jing Zhang et al.
CANCER AND METASTASIS REVIEWS (2007)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy
VL Damaraju et al.
ONCOGENE (2003)
Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection
H Yamaue et al.
PANCREAS (2002)
Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)
MWL Ritzel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Intra-arterial chemotherapy for unresectable pancreatic cancer
M Cantore et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
